Cargando…

A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache

Twenty-three patients, aged 18‐66 years and suffering from migraine with or without aura, were randomly selected to receive either vigabatrin or matched placebo tablets first for 12 weeks in a double-blind crossover study. Alternative treatment was given after a 4-week washout period. The dose of me...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghose, Karabi, Niven, Brian E., Berry, Dave
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag Italia 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613231/
http://dx.doi.org/10.1007/s101940200022
_version_ 1782264717942718464
author Ghose, Karabi
Niven, Brian E.
Berry, Dave
author_facet Ghose, Karabi
Niven, Brian E.
Berry, Dave
author_sort Ghose, Karabi
collection PubMed
description Twenty-three patients, aged 18‐66 years and suffering from migraine with or without aura, were randomly selected to receive either vigabatrin or matched placebo tablets first for 12 weeks in a double-blind crossover study. Alternative treatment was given after a 4-week washout period. The dose of medication was titrated to a maximum of 4 tablets (2 g vigabatrin) daily according to patients' tolerance during the first six weeks of each treatment. No further dosage adjustment was made. Apart from rescue medication for migraine, no other drug was permitted. Four patients dropped out and four were excluded for non-compliance. Compared to placebo, vigabatrin decreased the frequency (p=0.017) and severity (p=0.024) of headache modestly. However, it reduced the duration (p=0.019) of headache and migraine index (p=0.012) considerably by 40% and 59%, respectively. No serious adverse effects were observed. Serum vigabatrin levels showed no correlation with the clinical effects.
format Online
Article
Text
id pubmed-3613231
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Springer-Verlag Italia
record_format MEDLINE/PubMed
spelling pubmed-36132312013-04-01 A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache Ghose, Karabi Niven, Brian E. Berry, Dave J Headache Pain Original Twenty-three patients, aged 18‐66 years and suffering from migraine with or without aura, were randomly selected to receive either vigabatrin or matched placebo tablets first for 12 weeks in a double-blind crossover study. Alternative treatment was given after a 4-week washout period. The dose of medication was titrated to a maximum of 4 tablets (2 g vigabatrin) daily according to patients' tolerance during the first six weeks of each treatment. No further dosage adjustment was made. Apart from rescue medication for migraine, no other drug was permitted. Four patients dropped out and four were excluded for non-compliance. Compared to placebo, vigabatrin decreased the frequency (p=0.017) and severity (p=0.024) of headache modestly. However, it reduced the duration (p=0.019) of headache and migraine index (p=0.012) considerably by 40% and 59%, respectively. No serious adverse effects were observed. Serum vigabatrin levels showed no correlation with the clinical effects. Springer-Verlag Italia 2002-09 /pmc/articles/PMC3613231/ http://dx.doi.org/10.1007/s101940200022 Text en © Springer-Verlag Italia 2002
spellingShingle Original
Ghose, Karabi
Niven, Brian E.
Berry, Dave
A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
title A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
title_full A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
title_fullStr A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
title_full_unstemmed A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
title_short A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
title_sort double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613231/
http://dx.doi.org/10.1007/s101940200022
work_keys_str_mv AT ghosekarabi adoubleblindcrossovercomparisonoftheeffectsofvigabatrinwithplacebointhepreventionofmigraineheadache
AT nivenbriane adoubleblindcrossovercomparisonoftheeffectsofvigabatrinwithplacebointhepreventionofmigraineheadache
AT berrydave adoubleblindcrossovercomparisonoftheeffectsofvigabatrinwithplacebointhepreventionofmigraineheadache
AT ghosekarabi doubleblindcrossovercomparisonoftheeffectsofvigabatrinwithplacebointhepreventionofmigraineheadache
AT nivenbriane doubleblindcrossovercomparisonoftheeffectsofvigabatrinwithplacebointhepreventionofmigraineheadache
AT berrydave doubleblindcrossovercomparisonoftheeffectsofvigabatrinwithplacebointhepreventionofmigraineheadache